Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization

A recent clinical trial of a T-cell-based AIDS vaccine delivered with recombinant adenovirus type 5 (rAd5) vectors showed no efficacy in lowering viral load and was associated with increased risk of human immunodeficiency virus type 1 (HIV-1) infection. Preexisting immunity to Ad5 in humans could th...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Cheng, Cheng, Gall, Jason G. D., Nason, Martha, King, C. Richter, Koup, Richard A., Roederer, Mario, McElrath, M. Juliana, Morgan, Cecilia A., Churchyard, Gavin, Baden, Lindsey R., Duerr, Ann C., Keefer, Michael C., Graham, Barney S., Nabel, Gary J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology (ASM) 2010
Gaiak:
Vaccines and Antiviral Agents
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2798414/
https://ncbi.nlm.nih.gov/pubmed/19846512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00866-09
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak